Indegene Limited (NSE:INDGN)
India · Delayed Price · Currency is INR 601.50
+1.35 (0.22%)
Sep 4, 2026, 3:29 PM IST
Indegene Revenue
Indegene had revenue of 10.63B INR in the quarter ending June 30, 2026, with 39.73% growth. This brings the company's revenue in the last twelve months to 38.13B, up 30.41% year-over-year. In the fiscal year ending March 31, 2026, Indegene had annual revenue of 35.11B with 23.64% growth.
Revenue (ttm)
38.13B
Revenue Growth
+30.41%
P/S Ratio
3.80
Revenue / Employee
8.13M
Employees
4,687
Market Cap
144.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 35.11B | 6.71B | 23.64% |
| Mar 31, 2025 | 28.39B | 2.50B | 9.64% |
| Mar 31, 2024 | 25.90B | 2.84B | 12.29% |
| Mar 31, 2023 | 23.06B | 6.41B | 38.54% |
| Mar 31, 2022 | 16.65B | 6.84B | 69.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Apollo Hospitals Enterprise | 264.30B |
| Divi's Laboratories | 112.30B |
| Lenskart Solutions | 96.34B |
| Syngene International | 36.00B |
| NATCO Pharma | 34.85B |
| Marksans Pharma | 31.72B |
| Rainbow Children's Medicare | 18.20B |
Indegene News
- 5 weeks ago - Indegene Transcript: Q1 26/27 - Transcripts
- 5 weeks ago - Indegene Quarterly report: Q1 2027 - Filings
- 5 weeks ago - Indegene Slides: Q1 2027 - Filings
- 3 months ago - Indegene Slides: Investor presentation - Filings
- 4 months ago - Indegene Transcript: Q4 25/26 - Transcripts
- 4 months ago - Indegene Quarterly report: Q4 2026 - Filings
- 4 months ago - Indegene Slides: Q4 2026 - Filings
- 4 months ago - Indegene Annual report: Q4 2026 - Filings